La Jolla Pharmaceutical (LJPC) Getting Positive Media Coverage, Accern Reports
News headlines about La Jolla Pharmaceutical (NASDAQ:LJPC) have trended positive on Sunday, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. La Jolla Pharmaceutical earned a coverage optimism score of 0.31 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.3040894969881 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
La Jolla Pharmaceutical (NASDAQ LJPC) traded up $0.74 during mid-day trading on Friday, hitting $35.05. The stock had a trading volume of 256,414 shares, compared to its average volume of 213,896. La Jolla Pharmaceutical has a 52-week low of $14.63 and a 52-week high of $39.28.
La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.05. research analysts expect that La Jolla Pharmaceutical will post -4.94 EPS for the current fiscal year.
LJPC has been the topic of several research reports. Zacks Investment Research upgraded La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Wednesday. BidaskClub upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Chardan Capital restated a “buy” rating and set a $85.00 price target on shares of La Jolla Pharmaceutical in a research report on Tuesday, August 8th. Cowen and Company restated a “buy” rating and set a $55.00 price target on shares of La Jolla Pharmaceutical in a research report on Friday, October 27th. Finally, Jefferies Group LLC restated a “buy” rating and set a $40.00 price target on shares of La Jolla Pharmaceutical in a research report on Tuesday, July 25th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $52.00.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Stock Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related stocks with our FREE daily email newsletter.